OR-AIRSHIP
16.5.2019 15:02:09 CEST | Business Wire | Press release
Customer engagement company Airship today announced May and June dates and locations for its 2019 Customer Engagement Forum , a year-long global event series. These interactive sessions feature leaders from many of the world's leading brands discussing their plans and practices for customer engagement (CX) in a digital world — arming marketers with proven strategies, research and techniques to connect with customers in smarter, faster, and more effective ways.
Dubbed ELEVATE, the educational series will kick-off in Santa Monica on May 21, 2019 and San Francisco on May 30, 2019. In June, the forum series will come to Paris , Chicago , New York , Amsterdam and London . Seats are limited; those interested in attending should reserve their spot using the city-specific links above. Additional cities and dates will be announced later this year.
Featuring a unique collection of speakers in each city, the series will focus on the growing focus on customer experience (CX) as the key driver of many companies’ growth and competitive strategies. Among topics such as CX best practices and innovation, the program will also include a discussion of building a business case for the value of better customer experience (CX).
According to Gartner, “Today, slightly more than two-thirds of marketers responsible for CX say their companies compete on the basis of CX. In two years, this expectation rises even further, with 81% of respondents anticipating their companies will do so.” (Gartner, Customer Experience in Marketing Survey 2017: Greater Expectations, Greater Challenges, Augie Ray, Jane-Anne Mennella, Simon Yates, Refreshed April 9, 2019, Published 5 October 2017).
Customer Engagement Forum attendees will gain a sharper understanding of what’s at stake when it comes to getting customer engagement right — learning about the CX trends experts are watching, as well as the CX tech stack and common team structures. Beyond a notebook full of ideas to leapfrog the competition and crush their KPIs, attendees will gain stats to build a business case for the value of better CX to grow their budgets and their careers.
“Forrester analyzed the correlation between CX quality and revenue growth for companies in five industries ... companies with superior CX grew revenues five times faster on average than their competitors with inferior CX. And this is a global phenomenon” (Forrester Research, Inc., “Improving CX Through Business Discipline Drives Growth,” June 19, 2017; Updated March 26, 2018).
Companies speaking at Customer Engagement Forum events include AccuWeather, AMC Theatres, Expensify, Footlocker, France TV, GSN Games, Tribune Publishing, Turner Sports and Zillow, with more to come.
“Today’s fastest-growing brands separate themselves from the pack by providing unique experiences that deliver surprising convenience and delight to their customers,” said Mike Stone, SVP of Marketing, Airship. “The Airship Customer Engagement Forum provides marketers an incredible opportunity to learn successful CX strategies from leading brands, as well as the programs and tactics to put them into place.”
For more information on Airship’s Customer Engagement Forum 2019, or to register, please visit forum.airship.com .
About Airship
Marketing and digital experience teams at thousands of the world’s most admired companies rely on Airship’s Customer Engagement Platform to create deeper connections with customers by delivering incredibly relevant, orchestrated messages on any channel.
Founded in 2009 as a pioneer in push notifications, Airship now gives brands the user-level data, engagement channels, AI orchestration and services they need to deliver push notifications, emails, SMS, in-app messages, mobile wallet cards and more to exactly the right person in exactly the right moment — building trust, boosting engagement, driving action and growing value.
Learn more about our Customer Engagement Platform , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005238/en/
Contact:
North America: Dave Struzzi Bateman Group +1 415-697-2560 airship@bateman-group.com
Corey Gault Airship +1 503-206-9164 corey@airship.com
EMEA: Nicolas Vitre Airship +33 1 44 56 88 21 +33 6 88 04 76 86 nicolas.vitre@airship.com
UK: Lucinda Layton Hotwire UK +44 20 7608 2500 Airship@hotwireglobal.com
France: Marion Fajgenbaum / Marine Cressot Hotwire France +33 14 312 55 68 / 69 AirshipFR@hotwireglobal.com
Germany: Julia da Silva Bastos Hotwire Germany +49 89 2620 81 89 airshipde@hotwireglobal.com
Spain: Beatriz Pérez Hotwire Spain +34 917 44 1265 beatriz.perez@hotwireglobal.com
Italy: Sara Tetti Hotwire Italy +39 349 5788052 AirshipIT@hotwireglobal.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom